Search results for "25"

showing 10 items of 3263 documents

Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function

2021

A combination of albumin-bilirubin (ALBI) grading and the Prognostic Nutritional Index (PNI) was identified recently as a highly predictive tool for patients with hepatocellular carcinoma (HCC) undergoing tumor ablation. The present study evaluated this combination in patients undergoing transarterial chemoembolization (TACE). Between 2010 and 2020, 280 treatment-naïve patients were retrospectively identified. The influence of ALBI grade, PNI and the novel ALBI-PNI on the median overall survival (OS) was assessed. In the next step, the prognostic ability of the combined approach was compared to established scoring systems. Both ALBI grade 2−3 and a low PNI were highly predictive for median …

Cancer Researchmedicine.medical_specialtybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensalbumin-bilirubin gradehepatocellular carcinomatransarterial chemoembolizationprognostic nutritional indexmedicine.diseaseGastroenterologyConcordance indexCombined approachTumor ablationArticlerisk predictionOncologyInternal medicineHepatocellular carcinomamedicineOverall survivalIn patientLiver functionbusinessGrading (tumors)RC254-282Cancers
researchProduct

Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: Real-life experience from the French CAREPI study group

2021

Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value has not yet been demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemiplimab. Endpoints were best overall response rate (BOR), progression-free survival (PFS), overall survival (OS), duration of response (DOR) and safety. The 245 patients (mean age 77 years, 73% male, 49% prior systemic treatment, 24% immunocompromised, 27% Eastern Cooperative Oncology Group performance status (PS) ≥ 2) had laCSCCs (35%) or mCSCCs (65%). For the 240 recipients of ≥1 infusion(s), the BOR was 50.4% (complete, 21%

Cancer Researchmedicine.medical_specialtycutaneous squamous cell carcinomaLocally advancedBest Overall Response[SDV.CAN]Life Sciences [q-bio]/CancerGastroenterologyArticle030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicineOverall survivalMedicineAdverse effectGroup performanceRC254-282Immune statusbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensMean agemedicine.diseasechronic dermatosisToxic epidermal necrolysis3. Good healthimmunocompromisedreal-life settingOncology030220 oncology & carcinogenesisPD-1–blocking antibodycemiplimabbusiness[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
researchProduct

Cancer and Pregnancy: A Comprehensive Review

2021

Simple Summary The co-occurrence of cancer and pregnancy is fortunately a rare event. It is a challenging situation for all involved parties, as the risks and benefits of oncological treatments should be balanced for both the mother and the offspring. This work offers guidance to clinicians regarding the choice of diagnostic and therapeutic procedures, as well as regarding the management of the pregnancy. Abstract Cancer diagnosis and treatment in pregnant women is a challenging situation. A multidisciplinary network of specialists is required to guide both, the expecting mother and the unborn child through the diagnostic workup and the cytotoxic therapy, by balancing the respective risks a…

Cancer Researchmedicine.medical_specialtydiagnostic proceduresfetal outcomeReviewtherapeutic procedures03 medical and health sciences0302 clinical medicineUnborn childMultidisciplinary approachmedicinecancer030212 general & internal medicineRisks and benefitsStage (cooking)Intensive care medicineCytotoxic TherapyRC254-282PregnancyNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancermedicine.diseaseOncology030220 oncology & carcinogenesisFetal outcomepregnancyCancers
researchProduct

Hypofractionated Radiotherapy in Head and Neck Cancer Elderly Patients: A Feasibility and Safety Systematic Review for the Clinician

2021

ObjectiveRadiotherapy (RT) in the head and neck (H&N) site are undoubtedly the most challenging treatments for patients. Older and frail patients are not always able to tolerate it, and there are still no clear guidelines on the type of treatments to be preferred for them. The recommendations for Risk-Adapted H&N Cancer Radiation Therapy during the coronavirus disease 2019 (COVID-19) pandemic provided by the ASTRO-ESTRO consensus statement achieved a strong agreement about hypofractionated RT (HFRT). A systematic literature review was conducted in order to evaluate the feasibility and safety of HFRT for older patients affected by H&N malignancies.Materials and Method…

Cancer Researchmedicine.medical_specialtyelderly oncologymedicine.medical_treatmentelderlyEffective dose (radiation)medicinegeriatric oncologyRC254-282radiotherapyPerformance statushypofractionationbusiness.industryHead and neck cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseRadiation therapyRegimenSystematic reviewOncologyGeriatric oncologyConcomitanthead and neck cancerSystematic ReviewRadiologybusinessFrontiers in Oncology
researchProduct

Intermittent and Periodic Fasting, Hormones, and Cancer Prevention

2021

Simple Summary Hormonal and growth factor alterations, related to an elevated food consumption and excessive adiposity, affect the regulation of genes involved in cellular processes including proliferation, differentiation and DNA repair, allowing cells to survive and proliferate despite the accumulation of mutations which lead to malignant transformation. The growth hormone/insulin growth factor-1 (GH/IGF-1)/ insulin pathway and its downstream effectors, in fact, are known to promote aging and/or age-related diseases, including cancer, in many model organisms. The restriction of nutrients is established to have strong effects on levels of hormones and growth factors, delaying the incidence…

Cancer Researchmedicine.medical_specialtyfastingDNA damagemedicine.medical_treatmentReviewInternal medicinemedicineRC254-282Cancer preventioncancer preventionbusiness.industryInsulinRegeneration (biology)agingNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerImmunosenescencemedicine.diseasegrowth hormonesEndocrinologyOncologyCancer cellDNA damagebusinessHormoneCancers
researchProduct

Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty

2019

Gastrointestinal (GI) cancers are common in all parts of the world. Effective prevention and early detection of GI cancers are not universally implemented. Therefore, it must be anticipated that the incidence and the mortality of GI cancers will remain high within the next decades. The European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Faculty aims to increase the skills of medical oncologists and other disciplines involved in treating GI malignancies. We aimed to increase the survival chances for patients with GI cancers, augment their quality of life and enable successful return to normal social and professional life during the period of survivorship. ESMO also aims to d…

Cancer Researchmedicine.medical_specialtygastrointestinal cancerDelphi methodEarly detectionReviewlcsh:RC254-282decision makingmultidisciplinarity03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Survivorship curveparasitic diseasesMedicine030212 general & internal medicineGastrointestinal cancer1506educationbusiness.industryIncidence (epidemiology)social sciencesmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthOncology030220 oncology & carcinogenesisFamily medicinePosition paperpopulation characteristicsclinical trainingbusinessGi cancerhuman activities
researchProduct

Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications.

2019

Meningiomas account for approximately 30% of all new diagnoses of intracranial masses. The 2016 World Health Organization’s (WHO) classification currently represents the clinical standard for meningioma’s grading and prognostic stratification. However, watchful waiting is frequently the chosen treatment option, although this means the absence of a certain histological diagnosis. Consequently, MRI (or less frequently CT) brain imaging currently represents the unique available tool to define diagnosis, grading, and treatment planning in many cases. Nonetheless, these neuroimaging modalities show some limitations, particularly in the evaluation of skull base lesions. The emerging evidence supp…

Cancer Researchmedicine.medical_specialtypositron emission tomographymedicine.medical_treatmentReviewlcsh:RC254-282meningioma030218 nuclear medicine & medical imagingMeningioma03 medical and health sciences0302 clinical medicineNeuroimagingFunctional neuroimagingmedicineotorhinolaryngologic diseasesMedical diagnosisRadiation treatment planningGrading (tumors)neoplasmsMeningioma; Neuroimaging; Positron emission tomography; Radionuclide therapy; Somatostatin receptorneuroimagingbusiness.industryradionuclide therapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasesomatostatin receptorOncologymeningioma; somatostatin receptor; neuroimaging; positron emission tomography; radionuclide therapy030220 oncology & carcinogenesisRadionuclide therapyRadiologybusinessWatchful waitingCancers
researchProduct

Risk factors for recurrence after robot-assisted radical hysterectomy for early-stage cervical cancer: a multicenter retrospective study

2020

This retrospective analysis aimed to assess the risk factors for recurrence in patients diagnosed with early-stage cervical cancer (&le

Cancer Researchmedicine.medical_specialtyrecurrenceSentinel lymph nodelcsh:RC254-282Article03 medical and health sciences0302 clinical medicineBiopsyrobotic surgerymedicineRadical HysterectomyStage (cooking)CàncerCancerCervical cancer030219 obstetrics & reproductive medicinemedicine.diagnostic_testoncological outcomeCirurgiabusiness.industryHazard ratioRetrospective cohort studymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenshumanitiesbody regionsOncologyEstudi de casos030220 oncology & carcinogenesisradical hysterectomyearly-stage cervical cancerAdenocarcinomaSurgeryRadiologyCase studiesbusiness
researchProduct

A Multicentric Randomized Trial to Evaluate the ROle of Uterine MANipulator on Laparoscopic/Robotic HYsterectomy for the Treatment of Early-Stage End…

2021

ObjectiveThis prospective randomized trial aimed to assess the impact of the uterine manipulator in terms of lymph vascular space invasion (LVSI) in patients undergoing minimally invasive staging for early-stage endometrial cancer.MethodsIn this multicentric randomized trial, enrolled patients were randomly allocated in two groups according to the no use (arm A) or the use (arm B) of the uterine manipulator. Inclusion criteria were G1-G2 early-stage endometrial cancer at preoperative evaluation. The variables collected included baseline demographic characteristics, perioperative data, final pathology report, adjuvant treatment, and follow-up.ResultsIn the study, 154 patients (76 in arm A an…

Cancer Researchmedicine.medical_specialtyuterine manipulatormedicine.medical_treatmentUrologylaw.inventionRandomized controlled trialminimally invasive hysterectomylawmedicinehysterectomyStage (cooking)RC254-282Original ResearchHysterectomybusiness.industryEndometrial cancerrobotic hysterectomyNeoplasms. Tumors. Oncology. Including cancer and carcinogensPerioperativemedicine.diseaseendometrial cancer; hysterectomy; laparoscopic hysterectomy; minimally invasive hysterectomy; robotic hysterectomy; uterine manipulatorUterine manipulatorRobotic hysterectomyClinical trialSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologyendometrial cancerlaparoscopic hysterectomybusinessFrontiers in Oncology
researchProduct

Population-based study of breast cancer in older women: prognostic factors of relative survival and predictors of treatment

2012

Abstract Background A large proportion of women with breast cancer (BC) are elderly. However, there is a lack of information regarding BC prognostic factors and care in this population. The aims of this study were to assess the prognostic factors of relative survival (RS) among women with BC aged ≥ 75 years old and to identify the predictive factors of treatments administered to this population. Methods A population-based study was performed using data from the Cote d’Or breast and gynaecological cancer registry. Women aged 75 years and older with primary invasive BC and resident in Cote d’Or at the time of diagnosis made between January 1998 and December 2008 were retrospectively selected.…

Cancer Researchmedicine.medical_treatmentComorbidityBreast cancerBreast-conserving surgeryRegistriesMastectomyAged 80 and overeducation.field_of_studyPredictors of treatmentRelative survivalPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCombined Modality TherapyTreatment OutcomeOncologyPopulation SurveillanceHypertensionFemaleFranceMastectomyResearch Articlemedicine.medical_specialtyPopulationBreast NeoplasmsPrognostic factorsRelative survivallcsh:RC254-282Breast cancerDrug TherapyInternal medicineDiabetes MellitusmedicineAdjuvant therapyGeneticsHumansObesityElderly womeneducationSurvival analysisAgedNeoplasm StagingRetrospective StudiesGynecologyRadiotherapybusiness.industrymedicine.diseaseSurvival AnalysisLogistic ModelsMultivariate AnalysisHormone therapybusinessFollow-Up StudiesBMC Cancer
researchProduct